



FOR IMMEDIATE RELEASE

September 15, 2006, Boca Raton, FL:

Contact:

Larry J. Lapila
Vice President
Business Development
info@bpirx.com

Breckenridge Pharmaceutical, Inc. is pleased to announce that it has filed an Abbreviated New Drug Application ("ANDA") with the U.S. Food and Drug Administration for Oxcarbazepine Tablets 150, 300 and 600 mg ("Oxcarbazepine").

Oxcarbazepine, a prescription pharmaceutical product used in treating seizures, is currently marketed by Novartis Pharmaceuticals Corporation as Trileptal® Tablets. On the first date permitted by the Waxman-Hatch Act, Breckenridge filed a "Paragraph IV" certification with regard to U.S. Patent Number 7,037,525, which was issued to Novartis on May 2, 2006. In response to Breckenridge's Paragraph IV certification, Novartis, on September 5, 2006, filed a federal lawsuit against Breckenridge alleging patent infringement. Breckenridge denies the allegation of Novartis' complaint and is confident that it will prevail in the lawsuit.

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a privately-held pharmaceutical marketing research and development company founded in 1983, is headquartered in Boca Raton, FL, with offices in Berlin, CT, and Fairfield, NJ. Breckenridge markets over 100 products in many therapeutic categories to over 100 customers in all classes of trade.